Piramal Pharma
NSE: PPLPHARMA · ISIN INE0DK501011 · Healthcare
₹244.63−1.57 (−0.64%)
Monday 9 November, 12:04 IST. Delayed. Source: Yahoo Finance.
Price chart
₹244.63 −1.57 (−0.64%) today
The day
- Previous close
- ₹246.20
- Open
- ₹247.10
- Day high
- ₹250.40
- Day low
- ₹242.50
Listed on NSE since 19 October 2022.
Key numbers
- Market value
- ₹31,736 Cr
- EPS (trailing)
- ₹-1.58
- Price to book
- 4.10
- Dividend yield
- 0.00%
- Return on equity
- -2.6%
- Debt to equity
- 0.72
- Profit margin
- -2.1%
- Beta
- 0.22
- Volume today
- 33.57 L
- Average volume
- 63.29 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹7,032.41 Cr | ₹-186.46 Cr |
| FY24 | ₹8,106.41 Cr | ₹17.82 Cr |
| FY25 | ₹9,061.00 Cr | ₹91.13 Cr |
| FY26 | ₹8,758.82 Cr | ₹-325.94 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹2,617 Cr | ₹6 Cr | – |
| Q1 FY27Apr–Jun 2026 | ₹2,270 Cr | ₹-69 Cr | – |
| Q4 FY26Jan–Mar 2026 | ₹2,752 Cr | ₹-9 Cr | −105.7% |
| Q3 FY26Oct–Dec 2025 | ₹2,140 Cr | ₹-136 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹2,044 Cr | ₹-99 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹1,934 Cr | ₹-82 Cr | – |
Source: Piramal Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Piramal Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹5,462 Cr | ₹5,250 Cr |
| Investments | ₹324 Cr | ₹193 Cr |
| Inventories | ₹3,295 Cr | ₹3,064 Cr |
| Owed by customers | ₹2,254 Cr | ₹2,158 Cr |
| Cash and equivalents | ₹545 Cr | ₹1,200 Cr |
| Total assets | ₹18,537 Cr | ₹17,965 Cr |
| Borrowings | ₹5,665 Cr | ₹5,495 Cr |
| Total liabilities | ₹10,373 Cr | ₹9,802 Cr |
| Shareholders’ equity | ₹8,142 Cr | ₹8,163 Cr |
Source: Piramal Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Piramal Pharma
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 7,120
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Piramal Pharma in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 0.14 Per Share
Dividend · ex-date 16 July 2025
- Dividend - Rs 0.11 Per Share
Dividend · ex-date 12 July 2024
- Rights 5:46 @ Premium Rs 71/-
Right · ex-date 2 August 2023
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.